Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-3095 tablets, a targeted small molecule compound for allergic diseases [1] Group 1: Clinical Trial Approval - The company's subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has been authorized to conduct clinical trials for HRS-3095 tablets [1] - The approval signifies a significant step in the development of HRS-3095, which is expected to address allergic diseases effectively [1] Group 2: Product Development - HRS-3095 is a self-developed small molecule compound that shows promising results in preclinical studies, particularly in improving skin allergy symptoms in mice [1] - There are currently no approved drugs targeting the same mechanism for the CSU indication in both domestic and international markets [1] Group 3: Research Investment - The cumulative research investment for the HRS-3095 project has reached approximately 16.03 million yuan [1]